Print Page     Close Window     

SEC Filings

8-K
SEELOS THERAPEUTICS, INC. filed this Form 8-K on 02/06/2019
Entire Document
 

  1. "Reset Date" shall have the meaning ascribed to such term in the Series B Warrants.

  1. Intentionally omitted.

  1. "Reset Price" means the lower of (i) the Exercise Price then in effect and (ii) 125% of the applicable Reset Price (as defined in the Series B Warrants) determined as of the related Reset Date.

  1. Intentionally omitted.

  1. Intentionally omitted.

  1. "Series B Warrants" shall have the meaning ascribed to such term in the Securities Purchase Agreement.

  1. "Share Delivery Date" means the earlier of (i) the second (2nd) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case, following the date on which the Holder delivers the Exercise Notice to the Company, so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the earlier of (i) the second (2nd) Trading Day following the date on which the Company has received the Exercise Notice and (ii) the number of Trading Days comprising the Standard Settlement Period following the date on which the Company has received the Exercise Notice (provided that if the Aggregate Exercise Price has not been delivered by such date, the Share Delivery Date shall be one (1) Trading Day after the Aggregate Exercise Price (or notice of a Cashless Exercise) is delivered).

  1. "Standard Settlement Period" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Eligible Market with respect to the Common Stock as in effect on the date of delivery of the applicable Exercise Notice.

  1. "Subject Entity" means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.

  1. "Successor Entity" means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.

- 28 -



© Apricus Biosciences, Inc.